DBS System is a Swiss-based startup that produces the HemaXis portable blood test system. The latest news The company received $2.5 million in investment, of which Investiere invested $800,000, the Swiss pension fund Nest invested $700,000, and another $1 million from existing shareholders and angel investors.
DBS uses microfluidic technology to obtain more information from dried blood than traditional blood tests, making home testing easier. Its test method called "microsample" also requires less blood volume than existing methods.
The company's first generation of HemaXi equipment, HemaXis DB, is already available in Europe, and the company is building partnerships with companies in Europe and the United States. The financing was mainly for the development of a second-generation device called HemaXis DP, which passively separates plasma from serum without centrifugation or filtration.
“Our technical advantage is obvious: anyone can use it in a non- medical environment, reliable, safe and standardized blood samples, streamline logistics, and comply with existing workflows, all of which reduce laboratory costs.†Company CEO Eric Dman said in a statement. “This model is beneficial to us and our partners because they can expand their markets by reaching more patients and sell our equipment through their distribution network, which is estimated to reach $20 billion.
There are also many companies that are trying to revolutionize blood testing methods. At this year's CES conference, Seventh Sense Biosystems introduced their TAP device, which takes blood in two to three minutes without the need for a large needle. In addition, there are some home experiment test providers, such as Everlywell and myLabBox, which indicate that they are trying to get more insights from blood tests.
Parenteral Nutrition,Compound Amino Acid Injection 18Aa,Compound Amino Acid Injection 9Aa,Compound Amino Acid Injection 11Aa
Shandong Qidu Pharmaceutical Co., Ltd. , https://www.qdyypharma.com